Ottawa researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
While Dr. Bell and his colleagues have been investigating replicating viruses for the treatment of solid cancers for many years, with very promising results, this is the first major success they have had treating blood cancer (leukemia). It is also the first success they have had using a non-replicating virus-derived particle as opposed to a replicating virus.
“Our research indicated that a replicating virus might not be the safest or most effective approach for treating leukemia, so we decided to investigate whether we could make virus-derived particles that no longer replicate but still kill cancer,” said Dr. Conrad, a hematologist conducting research in the Blood and Marrow Transplant Program at The Ottawa Hospital, and currently completing his PhD at OHRI and uOttawa in the Department of Cellular and Molecular Medicine. “We were delighted to see that this novel therapy was very safe at high doses, and worked extremely well in our laboratory leukemia models. We hope to test this in patients in the near future.”
The researchers used a specific method and dose of UV light to transform regular replicating viruses into unique particles that could no longer replicate and spread, but could still enter cancer cells efficiently, kill them and stimulate a strong immune response against the cancer. These particles were able to kill multiple forms of leukemia in the laboratory, including samples taken from local patients who had failed all other therapies. Normal blood cells were not affected. This novel treatment was also successful in mouse models of leukemia. In fact, 80 per cent of the mice that received the therapy had markedly prolonged survival and 60 per cent were eventually cured, while all of the untreated mice died of their leukemia within 20 days.
“Leukemia is a devastating disease that can be very difficult to treat, and new therapies are urgently needed,” said Dr. Conrad. “While we’re still at the early stages of this research, I think this therapy holds a lot of promise because it appears to have a potent, long-lasting effect on leukemia without the debilitating side effects of many cancer therapies used in the clinic right now.
The Latest Bing News on:
- Recent Approaches in Hantavirus Vaccine Developmenton April 16, 2021 at 5:00 pm
*Hantavirus species with known pathology. In severe cases, low platelets and many immunoblasts Death in intractable cardiogenic shock, or spontaneous remission within 2 or 3 weeks With increasing ...
- Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hostson April 16, 2021 at 4:31 am
Thus, we established a packaging system to encapsidate DVG-A into virus-like particles (VLPs). We first needed to confirm that DVG-A could be encapsidated at all. To this end, we transfected ...
- Human Pluripotent Stem Cells in Pharmacological and Toxicological Screeningon April 15, 2021 at 5:00 pm
Human embryonic stem cells grow in small clumps and separation or cloning of single hESCs which retain pluripotency has not been reassuringly resolved. In hESC clumps, cells in the center and in ...
- An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primateson April 5, 2021 at 5:00 pm
Virus-derived replicon RNA (repRNA) vaccines were first described in 1989 and have been delivered in the forms of virus-like RNA particles, in vitro–transcribed RNA, and plasmid DNA (20–23). In repRNA ...
- COVID-19 Special Projecton March 14, 2021 at 4:42 pm
The polyprotein molecules are cleaved into more than a dozen fragments by the virus-derived “main protease” and “papain-like protease,” which are then used for viral proliferation and for the ...
- Prospects for improved bluetongue vaccineson September 16, 2020 at 10:10 am
A promising vaccine under development is based on virus-like particles that are made using baculovirus expression systems. These vaccines show high antigenicity and may require fewer rounds of ...
The Latest Google Headlines on:
The Latest Bing News on:
Non-replicating virus-derived particle
- Feed has no items.